Lexaria Bioscience Secures $3.5 Million in Direct Offering to Boost R&D
I'm PortAI, I can summarize articles.
Lexaria Bioscience Corp. has announced a $3.5 million registered direct offering, involving the sale of 2,661,600 shares and unregistered warrants. The funds will support R&D, working capital, and corporate purposes, enhancing its drug delivery technologies. The company is known for its DehydraTECH technology, improving drug bio-absorption and delivery. The latest analyst rating for LEXX stock is a Buy with a $4.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments